GHCM
ARRY

Glen Harbor Capital Management’s Array Biopharma Inc ARRY Stock Holding History

Glen Harbor Capital Management’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,036
Closed -$25K – 1351
2019
Q1 		$25K Buy
1,036
+700
+208% +$14.6K ﹤0.01% 1264
2018
Q4 		$5K Buy
+336
New +$5.1K ﹤0.01% 1274

Other funds holding ARRY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Glen Harbor Capital Management's ARRY Position: Q2 2019 in Review

Glen Harbor Capital Management sold out of Array Biopharma Inc (ARRY) in Q2 2019, closing a stake of 1,036 shares — an estimated $25K sold.

Glen Harbor Capital Management first reported a position in ARRY in Q4 2018 and held it in 2 quarters. The position peaked at $25K in Q1 2019. 319 funds tracked by Wall St. Rank hold ARRY as of Q2 2019.

  • Glen Harbor Capital Management reported no remaining Array Biopharma Inc position as of Q2 2019 after selling out during the quarter.
  • Glen Harbor Capital Management sold 1,036 Array Biopharma Inc shares in Q2 2019, an estimated $25K.
  • Glen Harbor Capital Management first reported a position in Array Biopharma Inc in Q4 2018 and held it in 2 quarters.
  • Glen Harbor Capital Management's Array Biopharma Inc position peaked at $25K in Q1 2019.
  • 319 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q2 2019.

Based on Glen Harbor Capital Management's 13F filing for Q2 2019, filed 13 Aug 2019.